|
Toxicities (RTOG Grade)
|
h-R3/RT (N = 7) [n (%)]
|
CDDP/RT (N = 7) [n (%)]
|
P Value*
|
|---|
|
WBC
| | |
0.102
|
|
(1&2)
|
3 (42.9%)
|
5 (71.4%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
PLT
| | |
0.059
|
|
(1&2)
|
5 (71.4%)
|
1 (14.3%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
HB
| | |
0.157
|
|
(1&2)
|
2 (28.6%)
|
5 (71.4%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
ALT
| | |
0.317
|
|
(1&2)
|
0 (0.00%)
|
1 (14.3%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
AST
| | |
0.317
|
|
(1&2)
|
0 (0.00%)
|
1 (14.3%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
GGT
| | |
1.000
|
|
(1&2)
|
0 (0.00%)
|
0 (0.00%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
Dermatitis
| | |
0.317
|
|
(1&2)
|
4 (57.1%)
|
7 (100%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
Rash
| | |
1.000
|
|
(1&2)
|
0 (0.00%)
|
0 (0.00%)
| |
|
(3&4)
|
0 (0.00%)
|
0 (0.00%)
| |
|
Mucositis
| | |
0.891
|
|
(1&2)
|
2 (28.6%)
|
3 (42.9%)
| |
|
(3&4)
|
4 (57.1%)
|
2 (52.4%)
| |
|
Taste change
| | |
1.000
|
|
yes
|
5 (71.4%)
|
6 (85.7%)
| |
|
no
|
2 (28.6%)
|
1 (14.3%)
| |
|
Vomit
| | |
0.020
|
|
only nausea
|
0 (0.00%)
|
1 (2.4%)
| |
|
Nausea and vomit
|
0 (0.00%)
|
5 (71.4%)
| |
|
Weight loss
| | |
0.174
|
|
(1&2)
|
2 (28.6%)
|
4 (57.1%)
| |
|
(3&4)
|
1 (14.3%)
|
2 (26.2%)
| |
- Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy
- * All p values were obtained by use of the paired rank sum test
